Roayaei Mahnaz, Nikanpour Yalda, Mahdavi Hoda
1Department of Radiotherapy and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran.
2Najaf-Abad Branch, Faculty of Medicine, Islamic Azad University, Isfahan, Iran.
Indian J Surg Oncol. 2019 Mar;10(1):213-218. doi: 10.1007/s13193-018-0830-y. Epub 2019 Jan 5.
Evidence to justify survival benefit of local therapy of the breast (LT) for breast cancer patients who are metastatic at presentation (MBC) is weak. The aim of this study is to evaluate the outcome of LT on survival in MBC patients. Patients who had received (1) radiotherapy, (2) surgery, (3) surgery and radiotherapy as LT, and (4) no LT in four groups of 25 were evaluated for 1- and 4-year cause-specific survival (CSS). One- and 4-year CSS in four groups were (1) 76% and 60%, (2) 84% and 56% (3) 80% and 52%, and (4) 48% and 16%, respectively. When controlling for age and site of metastasis as covariates, grouping significantly correlated with survival: (3, 94): 2.93, 0.04. Post hoc analysis revealed that the mean survival of group 2: ( 23.39, SE 2.53) was higher than group 4: ( 13.63, SE 2.52, = 0.03). Surgery as a single modality LT for MBC may provide survival benefit.
对于初诊时已发生转移的乳腺癌患者（MBC），支持局部治疗（LT）具有生存获益的证据不足。本研究旨在评估局部治疗对MBC患者生存的影响。对四组各25例分别接受了（1）放疗、（2）手术、（3）手术加放疗作为局部治疗以及（4）未接受局部治疗的患者进行1年和4年特异性生存（CSS）评估。四组患者的1年和4年CSS分别为：（1）76%和60%，（2）84%和56%，（3）80%和52%，以及（4）48%和16%。以年龄和转移部位作为协变量进行控制时，分组与生存显著相关：（3, 94）：2.93，P = 0.04。事后分析显示，第2组的平均生存期（23.39，标准误2.53）高于第4组（13.63，标准误2.52，P = 0.03）。手术作为MBC的单一局部治疗方式可能带来生存获益。
